MDMA-Assisted Therapy for Mental Healthcare Providers

Conditions

• Mental Wellbeing

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• MDMA Hydrochloride — DRUG
  Initial dose of 120 mg MDMA HCl in a therapeutic setting, followed 1.5 to 2 hours later by a supplemental dose of 40 mg MDMA HCl. Supplemental doses may be withheld if tolerability issues emerge or it is declined by the participant.

Study Details

This is a phase 1, open-label study to assess changes in mental well-being following MDMA administration within a therapeutic setting, in mental health providers who are in training to become MDMA assisted therapists. Secondary outcome measures will examine the effects on provider burnout, provider self-efficacy, mood, self-compassion, quality of life, and other psychological factors. Participants will work with a co-therapy pair as they engage in a preparatory session, one experimental session with MDMA, and an integration session the following day.

Key Dates

Start date

Feb 11, 2026

Status verified

Feb 2026

Primary completion

Sep 21, 2029

Completion

Dec 21, 2029

Study Design

Enrollment

30 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Arms

• Experimental: Open-Label
  One session of MDMA-Assisted Therapy

Primary Outcome Measure

Mental Health Continuum-Short Form (MHC-SF) [ Time Frame: At baseline and 28 days post-treatment ]

Central Contacts

• Lily Fischer
  862-253-1938
  [email protected]

Locations (1)

Find similar trials in New York, NY